By Doug Macron

Marina Biotech this week moved to head off a court order that would prevent it from using its new name, asking a US District Court to reject a request for a preliminary injunction by microRNA drugs startup Mirina as part of a trademark dispute between the firms.

In court filings obtained by Gene Silencing News, Marina argued that the two companies' names are sufficiently different that they would not be confused by the savvy and educated players in the RNAi and miRNA spaces.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.